Patient Satisfaction and Quality of Life Impact - PecFent®

Archimedes Development Ltd150 enrolled

Overview

National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions. • Study objectives include assessment of early treatment satisfaction.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Breakthrough Cancer Pain

Interventions

PecFent® (fentanyl) nasal sprayDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult (aged ≥18 years) with cancer * Taking at least 60 mg of oral morphine sulfate or equivalent per day for chronic background pain

Locations (1)

Hospital 12 de Octubre

Madrid, Spain

RECRUITING

Outcomes

Primary Outcomes

Satisfaction

Satisfaction will be assessed using a 4-point Likert scale.

Time frame: Satisfaction will be assessed approximately 1 hour after each breakthrough pain (BTPc) episode treated with PecFent® from completion of titration through Day 7

Central Contacts

Yolanda Riesgo, MD

CONTACT

+ 34 913510373 yolandariesgo@archimedespharma.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.